Lead Product(s): Silmitasertib
Therapeutic Area: Oncology Product Name: CX-4945
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Pediatric Brain Tumor Consortium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2021
Senhwa’s clinical partner, the Pediatric Brain Tumor Consortium, is currently conducting a Phase I/II and Surgical Study of Silmitasertib in both children and adults with recurrent SHH Medulloblastoma.